Jetbellin FXIIa inhibitor garadacimab: HAE reduces the number of seizures per month by 99%!
Last Update: 2020-06-17
Search more information of high quality chemicals, good prices and reliable suppliers, visit
During the study period, most patients treated with garadacimab did not have seizuresSpecifically, the three dose groups of garadacimab had 55.56 per cent, 87.5 per cent and 42.86 per cent of patients without any seizures, compared with 0 per cent in the placebo groupthe study, all adverse events were mild or moderate, and in all groups, the percentage of patients who experienced adverse events (TEAE) during at least one treatment was similarThe common TEAE is the erythema (12.5%) at the light and moderate injection siteOriginal source: CSL Behring Presents Results for Garadacimab as Sein Treatment in Heredity AngioedemaOriginal Title: Heredited Anedema (HAE) Innovative Therapy! Jetbellin FXIIa inhibitor garadacimab: Reduce the number of seizures per month by 99%!
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.